Stoke Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Stoke Therapeutics

08/08/2022 13:02

* Stoke Therapeutics Inc  STOK.OQ  reported a quarterly
adjusted
loss of 63 cents​​ per share for the quarter ended in June. The
mean expectation of nine analysts for the quarter was for a loss
of 69 cents per share.
    * Revenue was $3.23 million​; analysts expected $2.35
million. 
    * Stoke Therapeutics Inc's reported EPS for the quarter was
a loss
of 63 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Stoke Therapeutics Inc shares had risen by 27.1% this
quarter and lost 30.0% so far this year.
    * The company reported a quarterly loss of $24.65 million.
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $54.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 8
at 12:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.69          -0.63          Beat
 Mar. 31 2022      0.36           -0.66          Missed
 Dec. 31 2021      -0.62          -0.66          Missed
 Sep. 30 2021      -0.59          -0.61          Missed